RACHEL KENT: Open Payments
NPI 1548982739 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$253 in 14 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $27 · 2025 $253
Food & beverage: $253
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $52 |
| AstraZeneca Pharmaceuticals LP | 2 | $33 |
| Xeris Pharmaceuticals, Inc. | 1 | $30 |
| MAYNE PHARMA COMMERCIAL LLC | 4 | $25 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $25 |
| Novo Nordisk Inc | 1 | $24 |
| GlaxoSmithKline, LLC. | 1 | $23 |
| Hologic Sales and Service, LLC | 1 | $23 |
| ABBVIE INC. | 1 | $17 |
Products named: TRINTELLIX, AIRSUPRA, KEVEYIS, Quviviq, Wegovy, AREXVY, APTIMA, UBRELVY.
Industry payments across PA — which companies pay providers there.
